Selegiline transdermal system for the treatment of major depressive disorder: An 8-week, double-blind, placebo-controlled, flexible-dose titration trial

被引:70
作者
Feiger, Alan D.
Rickels, Karl
Rynn, Moira A.
Zimbroff, Dan L.
Robinson, Donald S.
机构
[1] RTA Colorado, Lakewood, CO 80401 USA
[2] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA
[3] Feiger Hlth Res Ctr, Wheat Ridge, CO USA
[4] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[5] Columbia Univ, New York State Psychiat Inst, Child & Adolescent Psychiat Div, New York, NY USA
[6] Pacific Clin Res Med Grp, Upland, CA USA
[7] Worldwide Drug Dev, Burlington, VT USA
关键词
D O I
10.4088/JCP.v67n0905
中图分类号
B849 [应用心理学];
学科分类号
040203 [应用心理学];
摘要
Objective: This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD). Method: Patients meeting DSM-IV criteria for MDD (N = 265) were randomly assigned to blinded treatment with STS or a matching placebo patch for 8 weeks. Patients failing to meet or maintain protocol-defined therapeutic response criteria at predetermined time points had their STS (or placebo) dose increased. Assessments were conducted at weeks 1, 2, 3, 5, 6, and 8. Patients were not required to follow a tyramine-restricted diet. The study ran from September 2001 through August 2002. Results: Selegiline transdermal system treatment resulted in significantly greater improvement (p <=.05) compared with placebo treatment on the 3 depression rating scales: the 28-item Hamilton Rating Scale for Depression (HAM-D-28) (primary outcome measure), the Montgomery-Asberg Depression Rating Scale, and the Inventory for Depressive Symptomatology-Self Rated. The treatment effect measured by the HAM-D-28 was modest, primarily due to insomnia side effects. The antidepressant efficacy of STS was substantiated further by the significantly greater improvement in core depression symptoms (HAM-D Bech-6 subscale). The side effects of highest incidence were application-site reactions and insomnia. There were no safety concerns based on routine clinical laboratory and electrocardiogram monitoring, and there were no occurrences of hypertensive crisis. Conclusion: Results of this double-blind, placebo-controlled, dose titration trial provide evidence of short-term efficacy, safety, and tolerability of STS in the dose range of 6 mg/24 hours to 12 mg/24 hours for treatment of MDD. Selegiline transdermal system has an improved margin of safety compared with oral monoamine oxidase inhibitors and represents a useful addition to the existing array of antidepressants.
引用
收藏
页码:1354 / 1361
页数:8
相关论文
共 33 条
[1]
A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder [J].
Amsterdam, JD .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (02) :208-214
[2]
The Hamilton depression rating scale: Has the gold standard become a lead weight? [J].
Bagby, RM ;
Ryder, AG ;
Schuller, DR ;
Marshall, MB .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (12) :2163-2177
[3]
QUANTITATIVE RATING OF DEPRESSIVE STATES [J].
BECH, P ;
GRAM, LF ;
DEIN, E ;
JACOBSEN, O ;
VITGER, J ;
BOLWIG, TG .
ACTA PSYCHIATRICA SCANDINAVICA, 1975, 51 (03) :161-170
[4]
HYPERTENSIVE INTERACTIONS BETWEEN MONOAMINE OXIDASE INHIBITORS AND FOODSTUFFS [J].
BLACKWELL, B ;
MARLEY, E ;
PRICE, J ;
TAYLOR, D .
BRITISH JOURNAL OF PSYCHIATRY, 1967, 113 (497) :349-+
[5]
Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients [J].
Bodkin, JA ;
Amsterdam, JD .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11) :1869-1875
[6]
THE MONOAMINE-OXIDASE INHIBITOR TYRAMINE INTERACTION [J].
BROWN, C ;
TANIGUCHI, G ;
YIP, K .
JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 29 (06) :529-532
[7]
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients [J].
Burke, WJ ;
Gergel, I ;
Bose, A .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (04) :331-336
[8]
Burke WJ, 2004, J CLIN PSYCHIAT, V65, P37
[9]
Prevalence of sexual dysfunction among newer antidepressants [J].
Clayton, AH ;
Pradko, JF ;
Croft, HA ;
Montano, CB ;
Leadbetter, RA ;
Bolden-Watson, C ;
Bass, KI ;
Donahue, RMJ ;
Jamerson, BD ;
Metz, A .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (04) :357-366
[10]
A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects [J].
Entsuah, R ;
Shaffer, M ;
Zhang, J .
JOURNAL OF PSYCHIATRIC RESEARCH, 2002, 36 (06) :437-448